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ABSTRACT
Objective: Mortality among adults of all ages
diagnosed with impaired glucose regulation (IGR) in
Tayside, Scotland, UK, was evaluated using routinely
collected healthcare data sets.
Research design and methods: Using record-
linked data in 2003–2008, all instances of blood
glucose testing in the population defined 2 cohorts of
patients aged 18+years: those with IGR (whether
impaired fasting glucose or impaired glucose tolerance
(IGT)) according to the WHO criteria, and those who
were normoglycemic. They were followed in survival
analyses for mortality or cardiovascular mortality
(censoring deaths that occurred within a 30-day period
of testing), to derive HRs (with 95% CI) for IGR status
using Cox regression, adjusted for age, sex, and an
area measure of deprivation.
Results: There were 2 372 712 tests for 214 094
patients, with 196 799 patients in the non-IGR cohort
and 50 080 in the IGR cohort. During follow-up,
19 147 (9.7%) and 8397 (16.8%) patients died in 2
cohorts, respectively, with mortality rates of 33.2/1000
patient-years and 70.7/1000 patient-years. In
multivariable analyses, the overall adjusted risk of
mortality for IGR was 1.16 (95% CI 1.13 to 1.20).
However, it was 2.59 (95% CI 2.17 to 3.10) for people
aged <45 years, decreasing to 0.94 (95% CI 0.85 to
1.00) in those aged 85+years. The HRs for
cardiovascular mortality were lower overall, but they
followed the same pattern, with statistically significant
increased risks for patients aged <64 years only. The
mortality risk was highest among patients with IGT.
Conclusions: IGR is associated with an increased
mortality risk which declines with age. It is therefore
important to prioritize young people with IGR for
prevention; but less important to be aggressive about
risk factor modification in older people.
Diabetes mellitus increases the risk of all-
cause and cardiovascular mortality.1
Impaired fasting glucose (IFG) and impaired
glucose tolerance (IGT), collectively known
as impaired glucose regulation (IGR) or pre-
diabetes, are diagnosed in patients whose
blood glucose levels are above the normal
range, but not high enough to be diagnostic
of diabetes.2 IFG and IGT can occur separ-
ately or in combination, and are associated
with an increased risk of type 2 diabetes.3
There is increasing evidence that these inter-
mediate states of hyperglycemia are also
associated with increased all-cause and car-
diovascular mortality. Risks for adverse out-
comes such as mortality or cardiovascular
mortality are likely to be continuous across
the glucose range, and diagnoses of IFG or
IGT represent arbitrary cut-off points,
depending also on whether fasting or 2 h
plasma glucose tests have been carried out.3
Despite this, wide variation exists in estimates
of the magnitude of these increased risks
between different studies.
For example, the Whitehall study showed
that IGT doubled the risk of mortality
from coronary heart disease among men
aged 40–64 years.4 Among older people
(50–75 years) in the Hoorn study, all-cause
and cardiovascular mortality increased as
Key messages
▪ Impaired glucose regulation (IGR; impaired
fasting glucose or impaired glucose tolerance) is
associated with an increased risk of mortality
and cardiovascular mortality.
▪ This increased risk is higher among patients with
impaired glucose tolerance.
▪ The increased risk decreases as age increases;
no increased risk of mortality associated with
IGR is evident among patients over the age of
85 years.
▪ It is important to prioritize young people with
IGR for prevention; but less important to be
aggressive about risk factor modification in older
people with IGR, thereby limiting the risk of
adverse side effects from inappropriate
medications.
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glycemic measures (2 h postload glucose and glycated
hemoglobin (HbA1c)) increased.5 Recently, in the
Australian Diabetes, Obesity and Lifestyle Study, the risk
of mortality was increased by 1.6-fold and 1.5-fold for 610
adults over 25 years with IFG and 1298 with IGT, respect-
ively, over mean follow-up of 5.2 years, when they
were compared with normoglycemic adults,6 but the
Cardiovascular Health Study found no independent
increased risk of mortality associated with prediabetes
among 4602 older people (>65 years) in the USA,7
neither did a German study of 1466 adults aged
55–74 years.8 In contrast, a US study using the National
Health and Nutrition Examination Survey over an 18-year
period showed that mortality was higher in patients with
prediabetes aged 35–74 years, although glycemic status in
this study was measured by HbA1c.9
It is likely that differences between studies are due to
underlying differences in the study populations and also
differences in measurement of IGR. While the deﬁni-
tions of IGT and IFG may be arbitrary, they do have
meaning for clinicians and patients. In this 6-year study,
we therefore evaluated the risk of mortality among all
adults diagnosed with IGR in Tayside, Scotland. By
including adults of all ages, we were able to examine dif-
ferences by age in particular detail.
RESEARCH DESIGN AND METHODS
This study was carried out using the data sources of the
Health Informatics Centre (HIC), University of Dundee,
for the population of Tayside, in Scotland, UK. HIC has
developed the record linkage of multiple, routinely
collected health data sets to carry out anonymized
diabetes research in the population of Tayside.
Electronic linkage is facilitated by the widespread use of
a 10-digit Community Health Identiﬁer (CHI) that is
assigned universally to all patients in Scotland when they
register with a general practitioner. Registration of these
patients is held on a central index.10
The speciﬁc data sets used for this study included a
biochemistry data set with records of all blood glucose
testing results for the Tayside population, a comprehen-
sive diabetes clinical information system (SCI-DC),
records of death certiﬁcation from the General Register
Ofﬁce for Scotland with a coded diagnosis for under-
lying cause of death, and demographic data held cen-
trally on the CHI index. This includes a quintile of
deprivation, known as Scottish Index of Multiple
Deprivation (SIMD), which is calculated using 38 area
indicators of access to services, education, employment,
crime, housing, health, and income.11 The demographic
breakdown of Tayside is broadly similar to that of the
rest of Scotland, with low proportions of residents from
ethnic minority groups.12
The 6-year study period was from January 2003 to
December 2008. All instances of blood glucose testing in
the population of Tayside during this time were identi-
ﬁed, after excluding non-valid records (eg, damaged
samples). Tests were classiﬁed as indicating a diagnosis of
IGT or IFG if the patient had undergone two blood
glucose tests on the same date (one coded in the data-
base as a fasting test with the second test assumed to be
carried out after an oral glucose tolerance test) that met
the WHO (6) criteria for IGT and IFG (IGT: ﬁrst test
<7.0 mmol/L and second test 7.8–11.0 mmol/L; IFG:
ﬁrst test 6.1–6.9 mmol/L and second test <7.8 mmol/L).
However, the majority of patients were found to have
only taken a fasting test. The WHO criteria allow a single
fasting test of 6.0–6.9 mmol/L to diagnose IFG
(although IGT and type 2 diabetes cannot be ruled out).
From these testing results, two cohorts of patients
were identiﬁed. They had to be at least 18 years at the
time of testing. Patients whose ﬁrst test during the study
period was diagnostic of diabetes were not included in
the study.
Non-IGR cohort: This cohort included all patients for
whom there was a record of blood glucose testing
during the 6-year study period that was not diagnostic of
IGR. Their index date was the date of the ﬁrst such test
during the study period. If they subsequently developed
IGR they moved into the IGR cohort.
IGR cohort: This cohort included all patients for
whom there was a record of blood glucose testing
during the 6-year study period that was diagnostic of
IGR. Their index date was the date of the ﬁrst such test
during the study period.
Patients in the two cohorts were followed to the study
end date (31 December 2008). If they left Tayside
before the study end date, they were censored, as were
patients in the non-IGR cohort who developed IGR
(censored at date of ﬁrst test diagnostic of IGR).
Similarly patients who were diagnosed with type 2
Table 1 Sociodemographic characteristics of non-IGR
and IGR cohort
Non-IGR cohort IGR cohort
Sex
Male 82 417 (41.9%) 23 858 (47.6%)
Female 114 382 (58.1%) 26 222 (52.4%)
Age category (years)
18–34 38 620 (19.6%) 3791 (7.6%)
35–44 28 454 (14.5%) 4206 (8.4%)
45–54 32 599 (16.6%) 6667 (13.3%)
55–64 35 498 (18.1%) 9849 (19.7%)
65–74 31 381 (15.9%) 10 966 (21.9%)
75–84 22 503 (11.4%) 10 266 (20.5%)
85+ 7742 (3.9%) 4335 (8.7%)
SIMD category
1 (least affluent) 35 967 (18.8%) 9302 (18.9%)
2 38 082 (19.9%) 10 006 (20.4%)
3 39 632 (20.7%) 10 069 (20.5%)
4 39 950 (20.8%) 10 027 (20.4%)
5 (most affluent) 38 192 (19.9%) 9761 (19.9%)
IGR, impaired glucose regulation; SIMD, Scottish Index of Multiple
Deprivation.
2 BMJ Open Diabetes Research and Care 2015;3:e000102. doi:10.1136/bmjdrc-2015-000102
Epidemiology/health services research
group.bmj.com on September 17, 2015 - Published by http://drc.bmj.com/Downloaded from 
diabetes were censored at the time of their diabetes
diagnosis. Otherwise, the primary outcome variable was
mortality that occurred at least 30 days after the index
date. Thus, if the patient died within 30 days of the
index date, they were censored at this date.
Using Cox regression to assess the risk of the primary
outcome variable (>30 day mortality), hazard ratios
(with 95% CIs) were determined in univariable analyses
for non-IGR versus IGR cohort, age at testing, sex, and
SIMD deprivation category. Those covariates that were
statistically signiﬁcant (p<0.05) in the univariable
analyses were entered into a multivariable model. The
analysis was then repeated for cardiovascular mortality
only. To be deﬁned as cardiovascular mortality, the
underlying cause of death on the death certiﬁcate had
to be ICD-10 coded as a cardiovascular diagnosis. The
adjusted hazard ratios were then determined for these
outcome variables in subgroups stratiﬁed by age.
The results for the fasting test were then extracted for
patients in the IGR cohort who were categorized into
four groups. The ﬁrst group were those who were known
to have IGT. The others were either diagnosed with
Table 2 Unadjusted and adjusted HRs (with 95% CI) for deaths after 30 days for all covariates: all-cause and cardiovascular
mortality
Total (n) Number of deaths* (%) Univariate Multivariate
All-cause mortality
Sex
Male 106 275 13 033 (12.3) 1.20 (1.17 to 1.24) 1.38 (1.35 to 1.42)
Female 140 609 14 511 (10.3) 1.00 1.00
Age category (years)
18–34 42 411 287 (0.7) 1.00 1.087† (1.086 to 1.088)
35–44 32 660 536 (1.6) 2.43 (2.07 to 2.85)
45–54 39 266 1226 (3.1) 4.72 (4.10 to 5.48)
55–64 45 347 2960 (6.5) 9.68 (8.45 to 11.08)
65–74 42 349 6059 (14.3) 21.54 (18.87 to 24.60)
75–84 32 769 9999 (30.5) 51.30 (44.98 to 58.51)
85+ 12 077 6476 (53.6) 115.39 (101.06 to 131.74)
SIMD category
1 (least affluent) 45 269 5782 (12.8) 1.23 (1.18 to 1.29) 1.70 (1.63 to 1.77)
2 48 088 5481 (11.4) 1.10 (1.06 to 1.15) 1.32 (1.26 to 1.37)
3 49 701 5357 (10.8) 1.06 (1.01 to 1.10) 1.18 (1.13 to 1.23)
4 49 977 5704 (11.4) 1.13 (1.09 to 1.18) 1.13 (1.09 to 1.18)
5 (most affluent) 47 953 4843 (10.1) 1.00 1.00
IGR status
No 196 799 19 147 (9.7) 1.00 1.00
Yes 50 080 8397 (16.8) 1.93 (1.87 to 1.98) 1.16 (1.13 to 1.20)
Cardiovascular mortality
Sex
Male 106 275 6573 (6.2 1.19 (1.14 to 1.25) 1.50 (1.43 to 1.67)
Female 140 609 7451 (5.3) 1.00 1.00
Age category (years)
18–34 42 411 28 (0.1) 1.00 1.116† (1.113 to 1.119)
35–44 32 660 137 (0.4) 10.85 (4.31 to 27.34)
45–54 39 266 403 (1.0) 31.32 (12.85 to 76.29)
55–64 45 347 1190 (2.6) 86.79 (35.97 to 209.40)
65–74 42 349 3024 (7.1) 239.69 (99.61 to 576.75)
75–84 32 769 5784 (17.7) 745.27 (310.0 to 1791.7)
85+ 12 077 3458 (28.6) 1910.1 (794.2 to 4593.4)
SIMD category
1 (least affluent) 45 269 2463 (5.4) 0.94 (0.89 to 1.10) 1.54 (1.42 to 1.67)
2 48 088 2686 (5.6) 0.99 (0.94 to 1.05) 1.28 (1.19 to 1.39)
3 49 701 2985 (6.0) 1.06 (1.01 to 1.12) 1.29 (1.20 to 1.40)
4 49 977 3006 (6.0) 1.09 (1.03 to 1.15) 1.14 (1.06 to 1.23)
5 (most affluent) 47 953 2681 (5.6) 1.00 1.00
IGR status
No 196 799 9897 (5.0) 1.00 1.00
Yes 50 080 4127 (8.2) 1.82 (1.72 to 1.92) 1.01 (0.96 to 1.07)
*Total includes all deaths (including those prior to 30 days).
†Age entered as continuous variable.
IGR, impaired glucose regulation; SIMD, Scottish Index of Multiple Deprivation.
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IFG or undeﬁned IGR (as previously described13).
Their fasting test results were categorized as <6.4, 6.4 to
<6.7, and 6.7+mmol/L. Hazard ratios for >30-day mortal-
ity and cardiovascular mortality were determined,
adjusted for other covariates.
The Tayside Committee for Medical Research Ethics
has granted general approval for studies using routinely
collected, anonymized health data.
RESULTS
There were 2 372 712 tests in Tayside during the study
period for a total of 214 094 patients. The majority
(around 90%) were single fasting tests. The ﬁnal
non-IGR cohort comprised 196 799 patients of at least
18 years of age, of whom 32 785 had a subsequent test
diagnostic of IGR, at which point they moved into the
IGR cohort. The IGR cohort comprised 50 080 patients.
The age and sex breakdown of the non-IGR and IGR
cohorts are presented in table 1. There was a higher pro-
portion of males in the IGR cohort, and higher propor-
tions of patients from less afﬂuent areas. The mean age
of patients was 63 years (median 65 years), compared
with 54 years in the non-IGR cohort (median 55 years).
In total, 2381 patients in the IGR cohort developed type
2 diabetes within the study period.
During follow-up, 19 147 (9.7%) patients died in the
non-IGR cohort; 8397 (16.8%) patients died in the IGR
cohort. Mean (median) follow-up time among all
patients was 1028 (1024) days: 1069 (1069) days for the
non-IGR cohort and 866 (806) days for the IGR cohort.
In the non-IGR cohort the mortality rate was 33.2 deaths
per 1000 patient years of follow-up. In the IGR cohort, it
was 70.7 deaths per 1000 patient years. A relatively high
proportion of deaths (15%) occurred within 30 days of
the index date, probably representing patients who had
their blood glucose levels tested on presentation with a
condition.
In Cox regression analyses (table 2), being male,
increasing age, and living in less afﬂuent areas were all
strongly associated with increasing risks of mortality
(when patients who died within 30 days of the index
date were censored). Patients in the IGR cohort were
nearly twice as likely to die compared with patients in
the non-IGR cohort. In multivariable analyses that then
adjusted for confounding by age, sex, and SIMD, the
Table 3 Adjusted HRs (with 95% CI) for deaths after 30 days for all covariates, stratified by age group: all-cause and
cardiovascular mortality
<45 years 45–64 years 65–84 years 85+years
All-cause mortality
Total deaths >30 days 667 3388 13 436 5778
Sex
Male 2.00 (1.71 to 2.34) 1.41 (1.31 to 1.50) 1.42 (1.37 to 1.47) 1.26 (1.18 to 1.33)
Female 1.00 1.00 1.00 1.00
Age 1.06 (1.05 to 1.07) 1.073 (1.068 to 1.080) 1.099 (1.096 to 1.103) 1.08 (1.07 to 1.09)
SIMD category
1 (least affluent) 2.79 (2.12 to 3.68) 2.34 (2.11 to 2.60) 1.65 (1.56 to 1.74) 1.26 (1.15 to 1.38)
2 2.06 (1.56 to 2.78) 1.63 (1.46 to 1.81) 1.29 (1.23 to 1.37) 1.16 (1.07 to 1.27)
3 1.09 (0.79 to 1.50) 1.14 (1.01 to 1.28) 1.19 (1.12 to 1.25) 1.18 (1.08 to 1.28)
4 1.16 (0.84 to 1.61) 1.07 (0.95 to 1.21) 1.17 (1.11 to 1.24) 1.04 (0.90 to 1.13)
5 (most affluent) 1.00 1.00 1.00 1.00
IGR status
No 1.00 1.00 1.00 1.00
Yes 2.59 (2.17 to 3.10) 1.69 (1.56 to 1.82) 1.12 (1.08 to 1.17) 0.94 (0.89 to 1.00)
Cardiovascular mortality
Total deaths >30 days 49 604 3862 2076
Sex
Male 1.43 (0.81 to 2.52) 2.28 (1.93 to 2.69) 1.53 (1.44 to 1.63) 1.19 (1.08 to 1.32)
Female 1.00 1.00 1.00 1.00
Age 1.21 (1.13 to 1.29) 1.11 (1.09 to 1.12) 1.13 (1.12 to 1.114) 1.08 (1.07 to 1.09)
SIMD category
1 (least affluent) 4.63 (1.60 to 13.41) 3.28 (2.52 to 4.27) 1.50 (1.36 to 1.66) 1.09 (0.93 to 1.66)
2 2.77 (0.90 to 8.50) 2.19 (1.66 to 2.89) 1.25 (1.13 to 1.37) 1.11 (0.95 to 1.29)
3 0.83 (0.21 to 3.31) 1.58 (1.19 to 2.11) 1.26 (1.14 to 1.40) 1.30 (1.14 to 1.49)
4 0.91 (0.23 to 3.63) 1.25 (0.92 to 1.70) 1.15 (1.04 to 1.27) 1.10 (0.97 to 1.26)
5 (most affluent) 1.00 1.00 1.00 1.00
IGR status
No 1.00 1.00 1.00 1.00
Yes 2.20 (1.12 to 4.33) 1.22 (1.01 to 1.48) 1.03 (0.96 to 1.10) 0.92 (0.83 to 1.01)
IGR, impaired glucose regulation; SIMD, Scottish Index of Multiple Deprivation.
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risk of IGR was still elevated, although lower. In analyses
for cardiovascular mortality only, increasing age, and
being male and less afﬂuent were all still strongly asso-
ciated with risk of mortality, but there was no increased
risk associated with being in the IGR cohort.
A formal test of interaction indicated that there was
interaction between age and IGR status (p<0.01); there-
fore, the results were stratiﬁed by age (table 3). The
increased mortality risks associated with IGR were stron-
gest in younger age groups. Patients aged <45 years had
over twice the risk of mortality if they were in the IGR
cohort. This risk decreased with increasing age and IGR
conferred no excess mortality to patients aged 85 years
or over. Although there was no increased risk for
cardiovascular mortality overall that was associated with
IGR, there was an increased risk evident for younger
patients (aged<65 years).
Among 50 080 patients with IGR, glucose values were
not available for 2244. Among the rest, there were 1891
patients in the IGR cohort who were diagnosed as
having IGT. Compared with patients with a fasting blood
glucose of <6.4 mmol/L (n=20 249), the adjusted hazard
ratio for >30-day mortality among patients with IGT was
1.61 (95% CI 1.45 to 1.79). For cardiovascular mortality,
it was 1.49 (95% CI 1.20 to 1.85). The risks for IFG are
presented in table 4, and increased slightly with increas-
ing blood glucose levels. A Kaplan-Meier survival plot
for overall mortality among these patients is shown in
ﬁgure 1, clearly showing the increased mortality con-
ferred by IGT.
CONCLUSIONS
This study in Tayside, Scotland, UK, shows that a diagno-
sis of IGR or prediabetes in a patient is associated with
an increased risk of mortality, when compared with indi-
viduals who have had a blood glucose test but who are
found to be normoglycemic. This excess risk decreases
as age increases, and is absent among people aged over
85 years. This probably explains some of the conﬂicting
evidence found on this association thus far. Several
studies that have identiﬁed no increased risk have been
restricted to older people.5 6 In this study, the increased
risk evident for cardiovascular mortality is lower than for
all-cause mortality, and no such increased risk is evident
for people older than 65 years.
Table 4 Adjusted HRs (with 95% CI) for deaths after
30 days associated with fasting glucose levels/IGT
IGR
category Total
Number of
>30 deaths
Adjusted HRs
(with 95% CI)
All cause mortality (mmol/L)
<6.4 20 249 2581 (12.7%) 1.00
6.4–6.69 14 380 2040 (14.2%) 1.07 (1.01 to 1.14)
≥6.7 11 316 1717 (15.2%) 1.12 (1.06 to 1.19)
IGT 1891 397 (21.0%) 1.61 (1.45 to 1.79)
Cardiovascular mortality (mmol/L)
<6.4 20 249 666 (3.3%) 1.00
6.4–6.69 14 380 584 (4.1%) 1.17 (1.05 to 1.31)
≥6.7 11 316 470 (4.2%) 1.16 (1.03 to 1.31)
IGT 1891 95 (5.0%) 1.49 (1.20 to 1.85)
IGR, impaired glucose regulation; IGT, impaired glucose
tolerance.
Figure 1 Kaplan-Meier survival
plot showing risk of mortality
stratified by fasting glucose
levels/impaired glucose tolerance
(IGT).
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It is important to note that the comparator population
of normoglycemic individuals in this study is not a
healthy control group. They are people who have had a
blood glucose test as part of their clinical care, for what-
ever reason (blood glucose tests are not carried out rou-
tinely in the UK), and are likely to be less healthy and
more medicalized than the general population. For this
reason, the risk ratios are probably all slightly underesti-
mated. We have no information on possible
lifestyle-related confounding factors, such as smoking or
body mass index, that are associated with increased mor-
tality and may be unequally distributed between the IGR
and the non-IGR cohort. Although adjustment for SIMD
may account for some of these differences (as adverse
lifestyle factors are often patterned by SIMD), it is difﬁ-
cult to predict whether adjustment for speciﬁc factors
would increase or decrease estimates of the HRs.
Despite these limitations, we still see clear patterns emer-
ging, particularly by age. Of relevance to clinicians and
public health practitioners is that the effects on mortal-
ity of IGR status, and also deprivation, are more pro-
nounced for younger patients (according with a
previous study in Tayside that showed that a diagnosis of
diabetes over the age of 65 years had a comparatively
weak association with mortality14). The association
between IGR and cardiovascular mortality appears to be
less strong than that for overall mortality, and there is a
less pronounced gradient for fasting plasma glucose
levels.
This study suggests that patients with IGT are the
highest risk group of patients with IGR, but that increas-
ing fasting plasma glucose levels among patients with
IFG are associated with increasing mortality. However, a
limitation to this study is the possibility of misclassiﬁca-
tion of IGR diagnoses. Although it was assumed that two
blood glucose results recorded on the same day repre-
sented a 2 h oral glucose tolerance test, this may not
have been true for every patient. It is also possible that
some IGT diagnoses were missed because the majority
of patients only underwent one test, and those who had
two may well have been sicker patients. The WHO cri-
teria allow a single fasting test of 6.0–6.9 mmol/L to
diagnose IFG (although IGT cannot then be ruled out).
Misclassiﬁcation of IGT in the IFG cohort would result
in a dilution of differences between the two groups, yet
we still see higher mortality in the IGT group. More
detailed analysis of the associations between fasting and
2 h plasma glucose tests, whether they are independent
of each other, and how they translate into excess mortal-
ity, is beyond the scope of this study, particularly given
the frequency of single fasting tests only. This large
record-linkage study has been carried out using well-
validated data sets. The biochemistry database is a
secure and complete record of all biochemical investiga-
tions for Tayside since 1993 and contains over 25 million
data items. Identiﬁcation of mortality relied on a
national data set of death certiﬁcation. We are therefore
conﬁdent in the robustness of the data and study
methods. The study highlights how important it is to pri-
oritize young people with IGR for prevention, not only
to reduce their risk of progression to type 2 diabetes13
but also to reduce their risk of mortality. Conversely, it is
less important to be aggressive about risk factor modiﬁ-
cation in older people with IGR, thus limiting the risk of
adverse side effects from inappropriate medications.
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